| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA801: Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer |
|
Medicine details |
|
| Medicine name | pembrolizumab (Keytruda®) |
| Formulation | 25 mg/ml concentrate for solution for infusion |
| Reference number | 3058 |
| Indication | In combination with chemotherapy, is indicated for the treatment of locally recurrent unresectable or metastatic triple negative breast cancer in adults whose tumours express PD-L1 with a CPS ≥ 10 and who have not received prior chemotherapy for metastatic disease |
| Company | Merck Sharp & Dohme Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 08/10/2021 |
| NICE guidance | |
| Commercial arrangement | PAS |